This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: American Heart Association Scientific Sessions 2020

December 2020

Inclisiran data shows good results LDL-C reduction across race and gender

BJC Staff

Abstract

Data presented at the recent American Heart Association Scientific Sessions 2020, showed pooled results from three ORION phase III trials in more than 3,600 patients with atherosclerotic cardiovascular disease (or heterozygous familial hypercholesterolemia (HeFH), who were given inclisiran at months 1, 3 and then every 6 months up to month 17. Results of the first analysis showed LDL-C reductions of approximately 51% from baseline for both women and men at 17 months. A second analysis demonstrated treatment with inclisiran lowered LDL-C similarly by approximately 51% across three age groups (<65, ≥65 to <75, and ≥75 years old). In b

| Full text
Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now